Balancing Genomic and Clinical Risk in HR+ Breast Cancer
Published: Tuesday, Sep 10, 2019
Nina D'Abreo, MD
In order to effectively tailor therapy to women with early-stage, hormone receptor (HR)–positive, HER2-negative breast cancer, equal consideration of a patient’s genomic and clinical risk is required, explained Nina D’Abreo, MD.
... to read the full story